FYI

UW-Madison researcher says stem cell benefits will take timeJoe Vanden Plas . Published 10/07/06

Madison, Wis. - When scientists look back at this early period in human embryonic stem cell discovery, they might regret the hype surrounding this controversial research, but they won't be able to accuse the man who derived stem cells from embryos of contributing to it.

Outlining some of the remaining challenges for stem cell researchers, University of Wisconsin-Madison professor James Thomson took the opportunity to inject some realism into the stem cell expectations game before
UW-educated executives at a CEO Summit convened by John Morgridge, chairman and former CEO of Cisco Systems.

The hype is coming from a variety of sources, and is creating expectations of near-term cures or treatments for debilitating diseases such as Alzheimer's and Parkinson's. While Thomson remains enthusiastic about the potential of stem cell research, he cautioned that its benefits will take time to realize, and he said that perhaps the biggest bang will come in ways that don't make the front pages of newspapers.

Noting that in retrospect, expectations for gene therapy have been oversold -breakthroughs have taken longer than many predicted - Thomson suggested that the same could be said of human embryonic stem cell research.

One of the promising areas of the research lies in the possibility of stem cell based transplantation therapy, but several obstacles remain. Perhaps the most daunting is preventing the process that originally kills cells, which he said could take years if not decades.

"I don't want to sound pessimistic," Thomson said. "This is all doable. It's just not going to happen overnight."
Dynamic research
Thomson serves as the scientific director for the UW's WiCell Research Institute, and co-founder of the drug-screening company Cellular Dynamics International along with fellow UW-Madison researchers Craig January and
Timothy Kamp.

The company plans to introduce a test for drug candidates for heart toxicity, and hopes to do limited cardiac toxic testing in human cardio myocytes - beating heart cells - in the first quarter of next year.

"It's Craig January's prior work," Thomson said. "Craig offers the gold standard for this particular cardiac test, and he's well respected throughout the drug industry, and it gives us immediate access to the market we're going to need for human embryonic stem cell testing."

Thomson believes the public debate on stem cells has shifted in favor of human embryonic stem cell research. Asked about the prospects of the mid-term elections producing a veto-proof majority for House Resolution 810, a bill that would make available new federal funding for stem cell research, he took a wait-and-see approach.
"I can't say," he said. "I'll just wait until November and see what happens.

I would say that clearly this work caused a fair amount of social controversy. It was well examined by a lot of different people, and it's broadly supported by the American public now.
"Politicians in Washington realize that, and whether it's this January or three years from now, the legislation will change."

One of the elected representatives who consistently has opposed H.R. 810 is Congressman Mark Green, who is challenging Doyle, a supporter of embryonic stem cell research, in the 2006 gubernatorial race. Asked what concerns him most about Green, who has called for $25 million in state support for
stem cell research that does not result in the destruction of embryos,

Thomson deflected the question.
"I so much try to stay out of local politics, but it's hard to do because the current governor has been very supportive of us," he said. "All I would say is, as much as this is important to people, it's worthwhile looking at the track records of both individuals and voting accordingly."

Thomson also said he doesn't worry that a challenge to the Wisconsin Alumni Research Foundation's stem cell patents will result in their being overturned or altered. That, he suggested, is WARF's concern. "So Carl [Gulbrandsen, WARF's managing director], his job is to get ulcers over that," Thomson said. "My job is to do good science."